ContraFect

ContraFect Cash Ratio

The Cash Ratio of ContraFect (CFRXQ) as of Oct 19, 2026 is 0.66. In the previous year, Cash Ratio was 4.46 — a change of -85.27% (lower).

Cash Ratio

0.66

YoY

-85.27%

Last updated:

Cash Ratio of ContraFect is 2022 0.66 . Cash Ratio of ContraFect was 2021 4.46 . It decreases by -85.27% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ContraFect Stock analysis

What does ContraFect do? ContraFect Corp, based in Yonkers, New York, is a clinical-stage biotechnology company focused on developing direct lytic agents (DLAs) such as lysins and amurin peptides to treat life-threatening antibiotic-resistant infections. The company, listed in 2014, employs 23 people and is advancing its lead candidate exebacase (CF-301) for MRSA bloodstream infections and chronic prosthetic joint infections, alongside CF-370 targeting gram-negative bacteria. ContraFect is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ContraFect stock

Cash Ratio of ContraFect is 0.66 in 2022.

Cash Ratio of ContraFect changed from 4.46 to 0.66, representing a -85.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Ratio ContraFect since 2006 – with annual values, charts, and detailed analysis.

The Cash Ratio is the most conservative liquidity metric, comparing only cash and equivalents to current liabilities.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Ratio's ContraFect with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — ContraFect

All Key Metrics — ContraFect